Recent Posts
Social•Feb 16, 2026
Pre‑market Rallies Set for Tomorrow’s Data Releases
Two Major Data Readouts Coming Tomorrow: $OCUL ripped in after-hours, +26% to ~$11.16, clear positioning into retina data. $CMPS has been quietly bid into its Phase 3 TRD readout, steady accumulation with mild pre-market strength. Both leaning long into the print. Now it’s about whether the data is strong enough to justify it.
By BowTiedBiotech
Social•Feb 16, 2026
China’s Biotech Boom: 5 Hidden Drivers & Future Forecasts
5 Hidden Themes Driving China’s Biotech Surge | Ep. 314 ...and 5 Bold Predictions for What’s Next https://t.co/TxBhvw5PG8 https://t.co/jTR63o431j
By BowTiedBiotech
Social•Feb 13, 2026
IMMX Gains Momentum as CAR‑T Landscape Heats Up
$IMMX momentum continues >Mizuho analyst initiates $14 PT >Lily acquisition of Orna Therapeutics $2.4 billion >AbbVie acquired Capstan Therapeutics $2.1 billion CAR-T heating up >Next milestone: imminent enrollment completion >Could NXC-201 be an eventual front-line therapy for AL Amyloidosis? >BLA submission projected Q3’26 https://t.co/cPpiiFHQal
By BowTiedBiotech
Social•Feb 13, 2026
CMPS Leads Psychedelic Push; HELP Gains Momentum
$CMPS first-in-line for potential psychedelic approval for Treatment Resistant Depression (TRD) . Likely war between "Old School FDA" and MAHA movement. Will be exciting to see the outcome. $HELP with strong data for Major Depressive Disorder (MDD) and Breakthrough Therapy Designation. New...
By BowTiedBiotech
Social•Feb 12, 2026
Capital Markets Reshape Translational Therapeutics Landscape
The Catalyst Machine | Ep. 931 How Capital Markets Quietly Rewired Translational Therapeutics https://t.co/lWNRxW0wuQ https://t.co/l14X2JfrLX
By BowTiedBiotech
Social•Feb 8, 2026
All Pharma Will Secure Chinese Clinical Development Partner Soon
Within the next 18-24 months every Pharma will have a partner to access the China fast clinical development engine https://t.co/zpLV1XJbvB https://t.co/h5CyXUNO82
By BowTiedBiotech
Social•Feb 6, 2026
IMMX Poised for Rise After Feb ’26 Enrollment Completion
$IMMX looks like it wants to move higher. Enrollment completion in Feb ’26 is the next key catalyst, setting up the path toward a filing-grade dataset in AL amyloidosis. Market starting to sniff it out. Check out the AL Amyloidosis success story here: https://t.co/1ei6kat25y
By BowTiedBiotech
Social•Feb 6, 2026
Undercutting Patents Erodes Funding for Medical Breakthroughs
Novo Nordisk spent billions developing GLP-1s. HIMS spent… a legal memo. Undercutting patented drugs while ignoring IP protections isn’t disruption... it’s erosion of the system that funds medical breakthroughs. 🔗 https://t.co/s63Kx8jBMf
By BowTiedBiotech
Social•Feb 3, 2026
BCMA CAR‑T Shows Near‑Perfect Response in AL Amyloidosis
BCMA CAR-T in AL amyloidosis is starting to look like a real category, not a case report. The Alpha: • Efficacy: 100% hematologic response rate, 78% CR • Durability: 100% PFS and OS at 12 months in a heavily pretreated cohort (median...
By BowTiedBiotech
Social•Jan 29, 2026
Biopharma Sentiment Surges, Fueling M&A and IPO Boom
Biopharma sentiment just snapped higher $XBI BPSI index jumped 78 to 90 in Q1. That is not a grind. That is a turn. Under the hood: >Current Conditions surged 58 to 75. Pain is easing now, not someday. >12-month Expectations hit 100 for the first...
By BowTiedBiotech
Social•Jan 27, 2026
CT‑388 Dual GLP‑1/GIP Shows Potent, Durable Weight Loss
Didn’t know $RHHBY was in obesity? They are. Genentech’s CT-388 (dual GLP-1/GIP) showed Ph2 data (n=469) & it might be differentiated (TBD): >48w: −22.5% PBO-adj (efficacy est) / −18.3% treatment-regimen >BMIpreDM to normoglycemia: 73% vs 7.5% >d/c: 5.9% vs 1.3% >No plateau; clear dose-response 💡Mechanistic...
By BowTiedBiotech